Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 14,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Heart Failure
Interventions: CDR132L, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 40 Years to 84 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 29
States / cities: Birmingham, Alabama • Tucson, Arizona • Covina, California + 24 more

Conditions: Reproductive Sterilization
Interventions: Adiana Transcervical Sterilization System; Device
Lead sponsor: Hologic, Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 770 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2013
U.S. locations: 14
States / cities: Phoenix, Arizona • Roseville, California • San Rafael, California + 11 more

Conditions: Alzheimer Disease
Interventions: Gantenerumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 1,053 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 33
States / cities: Tucson, Arizona • Irvine, California • Sacramento, California + 29 more

Conditions: Psoriasis
Interventions: placebo, CT 327; Drug
Lead sponsor: Creabilis SA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 5
States / cities: Charlotte, North Carolina • Wilmington, North Carolina • Winston-Salem, North Carolina + 2 more

Conditions: Patient Handoff
Interventions: Handoff Workshop; Other
Lead sponsor: George Washington University; Other
Eligibility: Not listed
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Dementia
Interventions: Tailored Activity Program, Home Safety and Education Program; Behavioral · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Scleroderma, Systemic
Interventions: Riociguat (Adempas, BAY63-2521), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 10
States / cities: Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 7 more

Conditions: Generalized Anxiety Disorder
Interventions: SEP-363856, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 11
States / cities: Redlands, California • Orlando, Florida • Watertown, Massachusetts + 8 more

Conditions: Fragile X Syndrome
Interventions: STX209, Placebo; Drug
Lead sponsor: Seaside Therapeutics, Inc.; Industry
Eligibility: 6 Years to 40 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 12
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 9 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Itepekimab SAR440340, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 1,127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 75
States / cities: Birmingham, Alabama • Jasper, Alabama • Chandler, Arizona + 56 more

Conditions: Dental Caries
Interventions: C16G2 Gel, Placebo; Drug · Other
Lead sponsor: Armata Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: Imperial Beach, California • Indianapolis, Indiana • Boston, Massachusetts + 6 more

Conditions: Focal Epilepsy
Interventions: BHV-7000, Placebo; Drug
Lead sponsor: Biohaven Therapeutics Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 50
States / cities: Peoria, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 41 more

Conditions: Recurrent Vulvovaginal Candidiasis
Interventions: VT-1161, Placebo; Drug
Lead sponsor: Viamet; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 32
States / cities: Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 27 more

Conditions: Cardiac Implantable Electronic Device Infection, Cardiovascular Infections
Interventions: Force gauge; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Obesity
Interventions: Ribupatide, Semaglutide, Placebo; Drug
Lead sponsor: Kailera; Industry
Eligibility: 18 Years and older
Enrollment: 1,270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 28
States / cities: Glendale, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 24 more

Conditions: Wound Closure, Wound Care
Interventions: Microlyte DualGuard, Allevyn Foam (Standard of Care Control); Device
Lead sponsor: Imbed Biosciences; Industry
Eligibility: 22 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia • New Orleans, Louisiana

Conditions: Prosocial Behavior, Self Regulation, Impulsive Behavior
Interventions: Calm & Alert yoga and mindfulness; Behavioral
Lead sponsor: Elizabethtown College; Other
Eligibility: 4 Years to 6 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Elizabethtown, Pennsylvania

Conditions: Obstructive Sleep Apnea, Hypertension
Interventions: Lorundrostat, Placebo; Drug
Lead sponsor: Mineralys Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 27
States / cities: Tuscaloosa, Alabama • Chandler, Arizona • Little Rock, Arkansas + 24 more

Conditions: Chronic Kidney Failure
Interventions: Fermagate, Placebo; Drug
Lead sponsor: Ineos Healthcare Limited; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 4
States / cities: Pine Bluff, Arkansas • Stuttgart, Arkansas • Charlotte, North Carolina

Conditions: Ulcerative Colitis
Interventions: Adalimumab, Adalimumab Placebo, Etrolizumab, Etrolizumab Placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 9
States / cities: Lakewood, Colorado • Maitland, Florida • Naples, Florida + 6 more

Conditions: Diabetic Diarrhea, Diabetes, Diarrhea
Interventions: Eluxadoline 100 mg; Drug
Lead sponsor: Temple University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Seborrheic Dermatitis
Interventions: Roflumilast Foam 0.3%, Vehicle foam; Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 22
States / cities: Fremont, California • Santa Monica, California • Coral Gables, Florida + 19 more

Conditions: Diarrhea Predominant Irritable Bowel Syndrome
Interventions: ASP7147, Placebo; Drug
Lead sponsor: Seldar Pharma, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 13
States / cities: Phoenix, Arizona • Encino, California • La Mesa, California + 9 more

Conditions: Left Ventricular Insufficiency
Interventions: CD-NP, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

Safety & Efficacy Study of the Adiana System for Women Who Desire Permanent Birth Control (Sterilization)

Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

CT 327 in the Treatment of Psoriasis Vulgaris

Effect of Hand-off Skills Training for Students During the Medicine Clerkship

Reducing Agitation in People With Dementia: the Customized Activity Trial

Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis

A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety Disorder

Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

Phase 2 Study to Evaluate the Microbiology and Safety of C16G2 Administered to Adult and Adolescent Dental Subjects

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

Improving Safety of Lead Extraction Procedures by Traction Force Sensing

Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

Safety Study of Microlyte DualGuard

Effects of Mindfulness and Yoga on Preschool Students' Emotional Regulation, Behavior, and Social Participation

A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension

Efficacy and Safety Study of Magnesium Iron Hydroxycarbonate for the Reduction of High Blood Phosphate in Hemodialysis Patients

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors

Investigation of Eluxadoline for Diabetic Diarrhea

Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

Safety Study of Chimeric Natriuretic Peptide(CD-NP) in Stable LVAD Patients